Moreover, even when surgery is utilized, there are cases where positive margins remain, in which case imatinib would be an option, often in combination with surgery.
Imatinib can decrease tumor size preoperatively and help to improve postsurgical aesthetic appearance and minimize functional impairment.
Gastrointestinal stromal tumour (GIST).
Imatinib was effective against GIST that were positive for KIT protein.
More micro-GIST are discovered with the development of investigations, rising the question of wait and see policy for some of them.
Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis.
For CML we analysed imatinib, dasatinib and nilotinib.
In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment.
Imatinib is the first effective systemic therapy for advanced GIST.
.
